Search
Menu
Home
HTB
2011
May
HTB
May 2011
Contents
Editorial
Volume 13 Number 5/6 May/June 2011
Conference reports
First Workshop on Nanomedicine for Infectious Diseases of Poverty, 27-31 March 2011, Magaliesberg, South Africa
17th Annual Conference of the British HIV Association (BHIVA), 6-8 April 2011, Bournemouth
Atazanavir in pregnancy: 155 cases in London clinics
Co-morbidity and late presentation – findings from an over 50s cohort
Health outcomes for young adults with perinatally acquired HIV infection following transfer to adult services
The use of calcaneal stiffness index to screen for osteoporosis in HIV-infected individuals
Frequency and characteristics of long-term non-progressors and HIV controllers in the Chelsea and Westminster cohort
Cerebral function in perinatally HIV infected young people and HIV uninfected sibling controls
An audit of HIV care provision for Immigration Removal Centre patients
12th International Workshop on Clinical Pharmacology of HIV Therapy, 13-15 April 2011, Miami
Quad reduces levels of oral contraceptives
Elvitegravir/cobicistat and acid reducing agents
Lopinavir/r reduces levels of rifabutin
Cobicistat has little impact on CYP2D6 and CYP2B6
Atazanavir levels indicate need for higher dose during pregnancy
Etravirine lowers levels of maraviroc given at 300 or 600 mg twice daily
Once-daily 150-mg maraviroc explored in people taking atazanavir/ritonavir
Lopinavir troughs lower in children on once-daily dose with efavirenz
Dose optimisation: 50 mg ritonavir-boosting, 3TC dosing and raltegravir once-daily
46th European Association for the Study of the Liver (EASL), 30 March-3 April 2011, Berlin, Germany
Rapid report: state of HCV policy, treatment, access
18th Conference on Retroviruses and Opportunistic Infections (CROI), 27 February-3 March 2011, Boston
When to start ART in patients co-infected with TB: results from two trials presented at CROI
Inflammation and intervention: how does HIV cause AIDS and how does it cause disease despite ART
PK and drug interactions
Meeting report from 12th Pharmacology Workshop, Miami
Meeting report from 18th CROI, Boston
Atazanavir/ritonavir and combined oral contraceptives
Side effects
Tenofovir associated with fewer side-effect related switches compared to AZT or d4T in first-line treatment
HIV prevention and transmission
FEM-PrEP prevention study using daily Truvada halted during enrolment: interim analysis shows similar infection rates in active and placebo arms
Basic science and immunology
Reduced HIV replication in CD4 T cells from elite controllers
More studies on the loss of naive T cells
The immunological effects of old age and anti-CMV immunity in HIV infection
BHIVA news
BASHH/BHIVA PEPSE guidelines for comment (2011)
UK national guideline on safer sex advice
Other news
Job vacancy: Treatment activist post at i-Base
On the web
Community resources and publications
PDFs
Volume 12 Number 5/6 May/June 2011 PDF
HTB RSS
Current issues
October 2024
September 2024
August 2024
Back issues
Special report
HIV diagnoses in England jump by 51% in 2023: missing targets and highlighting disparities in access to care
6 October 2024
More from HTB
Conference reports
Conference shortcuts
Articles by subject
PDFs
Subscribe
HTB homepage
Home
i-Base homepage